COMPARISON OF CLINICOPATHOLOGICAL AND SURVIVAL ANALYSIS OF ENDOMETRIAL DEDIFFERENTIATED, UNDIFFERENTIATED CARCINOMAS AND CARCINOSARCOMAS
DOI:
https://doi.org/10.55519/JAMC-03-13746Abstract
Background: Endometrial cancer ranks as the sixth frequently detected cancer and the 14th highest contributor, to cancer-related fatalities, among women globally. High-grade endometrial carcinomas encompass a diverse array of clinically aggressive tumors, including FIGO grade 3 endometrioid adenocarcinoma, uterine papillary serous carcinoma (UPSC), clear cell carcinoma, undifferentiated carcinoma, dedifferentiated carcinoma, and carcinosarcoma. The classification and diagnosis of these tumors pose challenges due to the absence of well-established molecular markers or panels The main purpose of this study is to assess and compare the clinicopathological characteristics of and survival rates of undifferentiated endometrial carcinoma (UEC), dedifferentiated carcinoma (DEC), and carcinosarcoma (CS) in the Pakistani population at SKMCH&RC. Methods: All patients diagnosed with DEC, UEC, and CS were analyzed from January 2011 and December 2022. Clinicopathological and survival data was retrospectively reviewed and analyzed using SPSS version 27. Kaplan-Meier analysis was used to calculate overall survival (OS) and disease-free survival (DFS). Results: Among 71 selected patients, 47.9% had CS, 29.6% had DEC, and 22.5% had UEC. Mean±S.D age at diagnosis was 58.18±11.35 years. A statistically significant association of DEC, UEC, and CS was identified (p-value <0.05) with myometrial invasion (p=0.02), lymphovascular invasion(p=0.006), positive margins(p=0.003), and involvement of adnexa/ parametria/ vaginal /other organ (p=0.01). The commonest pathological stage was pT1 38(53.5%). 56.3% of patients received chemotherapy, 29.6% received radiotherapy, and 38.0% received a combination of chemotherapy and radiation treatment. Recurrence occurred in 19.7% and death occurred in 37.7% of patients. The highest 5-year OS rate for pathological stage 1 was 59.1% (95% C.I: 42.9–81.3%) and 5-year-DFS was 62.2% (95% C.I: 42.9–81.3%). Conclusion: Patients diagnosed at an early pathological stage demonstrate better survival outcomes compared to an advanced stage, as documented in previous studies. Nevertheless, survival rates remain lower than Western population, indicating a necessity for gathering additional clinical data and alter the management strategies in our population.References
Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978–2013. JNCI: Journal of the National Cancer Institute. 2018 Apr 1;110(4):354-61.
Kobayashi Y, Kitazono I, Akahane T, Yanazume S, Kamio M, Togami S, et al. Molecular evaluation of endometrial dedifferentiated carcinoma, endometrioid carcinoma, carcinosarcoma, and serous carcinoma using a custom-made small cancer panel. Pathology & Oncology Research. 2021 Dec 23;27:1610013.
Huvila J, Pors J, Thompson EF, Gilks CB. Endometrial carcinoma: molecular subtypes, precursors and the role of pathology in early diagnosis. The Journal of Pathology. 2021 Apr;253(4):355-65.
Santoro A, Angelico G, Travaglino A, Inzani F, Arciuolo D, Valente M, et al. . New pathological and clinical insights in endometrial cancer in view of the updated ESGO/ESTRO/ESP guidelines. Cancers. 2021 May 26;13(11):2623.
Kasius JC, Pijnenborg JM, Lindemann K, Forsse D, van Zwol J, Kristensen GB, et al. Risk stratification of endometrial cancer patients: FIGO stage, biomarkers and molecular classification. Cancers. 2021 Nov 22;13(22):5848.
Hamilton SN, Tinker AV, Kwon J, Lim P, Kong I, Sihra S, et al. Treatment and outcomes in undifferentiated and dedifferentiated endometrial carcinoma. Journal of Gynecologic Oncology. 2022 May;33(3).
Li Z, Zhao C. Clinicopathologic and immunohistochemical characterization of dedifferentiated endometrioid adenocarcinoma. Applied Immunohistochemistry & Molecular Morphology. 2016 Sep 1;24(8):562-8.
Bansal N, Herzog TJ, Seshan VE, Schiff PB, Burke WM, Cohen CJ, et al. Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior. Obstetrics & Gynecology. 2008 Jul 1;112(1):64-70.
Lakhwani P, Agarwal P, Goel A, Nayar N, Pande P, Kumar K. High-Grade Endometrial Cancer—Behaviour and Outcomes at a Tertiary Cancer Centre. Indian Journal of Surgical Oncology. 2019 Dec;10(4):662-7.
Murali R, Davidson B, Fadare O, Carlson JA, Crum CP, Gilks CB, et al. High-grade endometrial carcinomas: morphologic and immunohistochemical features, diagnostic challenges and recommendations. International Journal of Gynecological Pathology. 2019 Jan 1;38:S40-63.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Usman Hassan, Iram Asrar, Hina Maqbool, Mudassar Hussain, Maryam Hameed, Asif Loya
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.